Retatrutide (a triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors) is a 39-amino-acid synthetic peptide currently in Phase 3 clinical research under the development designation LY3437943
Social divides persist: 73% of women and 61% of men feel pressure to lose weight
Glucagon-like peptide 1 agonist and effects on reward behaviour: a systematic review
Among the largest firms with at least 5,000 workers, more than a quarter (28%) say they cover GLP-1 drugs, and nearly two thirds (64%) say they dont
doi:10.1038/s41398-019-0515-5 Paddon-Jones D, Westman E, Mattes RD, Wolfe RR, Astrup A, Westerterp-Plantenga M
Tell your provider immediately if you notice a lump in your neck, difficulty swallowing, or persistent hoarseness